Pfizer growth drug for children gets US approval

The belated approval lifted Pfizer's shares marginally and those of its partner, Opko Health, by nearly 19% in premarket trading

The US Food and Drug Administration has approved Pfizer and partner Opko's treatment for growth hormone deficiency in children. 

The approval, which comes after an initial rejection from the FDA in January last year, lifted Pfizer's shares marginally and Opko Health's nearly 19% in premarket trading.